Revance Therapeutics (RVNC) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Revance Theraputics (RVNC) Pipeline is Underappreciated - Guggenheim
March 3, 2016 9:05 AM ESTGuggenheim analyst, Louise Chen, believes Revance Therapeutics' (NASDAQ: RVNC) pipeline prospects are underappreciated. She expects five launches over five years beginning in '19 that should drive upward earnings revisions and multiple expansion to levels not reflected in consensus expectations. No change to Buy rating or $55 PT.
The launches include:
1) RT001, topical for Crows Feet Lines in '19
2) RT002, injectable for glabellar... More
